Rock Springs Capital Management’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-410,000
| Closed | -$24.5M | – | 143 |
|
|
2019
Q4 | $24.5M | Hold |
410,000
| – | – | 0.78% | 52 |
|
|
2019
Q3 | $11.5M | Hold |
410,000
| – | – | 0.46% | 67 |
|
|
2019
Q2 | $15.5M | Sell |
410,000
-112,500
| -22% | -$4.32M | 0.56% | 65 |
|
|
2019
Q1 | $20.4M | Buy |
522,500
+22,500
| +5% | +$645K | 0.79% | 46 |
|
|
2018
Q4 | $10.7M | Buy |
500,000
+74,975
| +18% | +$1.93M | 0.5% | 65 |
|
|
2018
Q3 | $16.8M | Sell |
425,025
-14,975
| -3% | -$558K | 0.61% | 58 |
|
|
2018
Q2 | $16.8M | Sell |
440,000
-125,000
| -22% | -$4.63M | 0.65% | 56 |
|
|
2018
Q1 | $17M | Buy |
565,000
+40,000
| +8% | +$1.35M | 0.72% | 50 |
|
|
2017
Q4 | $16.4M | Hold |
525,000
| – | – | 0.74% | 47 |
|
|
2017
Q3 | $14.7M | Sell |
525,000
-70,200
| -12% | -$1.52M | 0.68% | 51 |
|
|
2017
Q2 | $11.4M | Buy |
595,200
+95,200
| +19% | +$1.52M | 0.58% | 57 |
|
|
2017
Q1 | $8.52M | Buy |
500,000
+15,000
| +3% | +$243K | 0.49% | 66 |
|
|
2016
Q4 | $8.86M | Hold |
485,000
| – | – | 0.59% | 53 |
|
|
2016
Q3 | $8.64M | Buy |
+485,000
| New | +$7.36M | 0.54% | 55 |
|
Rock Springs Capital Management's BOLD Position: Q1 2020 in Review
Rock Springs Capital Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 410,000 shares — an estimated $24.5M sold.
Rock Springs Capital Management first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $24.5M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Rock Springs Capital Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Rock Springs Capital Management sold 410,000 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $24.5M.
- Rock Springs Capital Management first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- Rock Springs Capital Management's Audentes Therapeutics, Inc position peaked at $24.5M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Rock Springs Capital Management's 13F filing for Q1 2020, filed 15 May 2020.